Late-extended adjuvant treatment: Does it work?

Diana Crivellari

doi:10.2217/1745509X.4.3.237

Late-extended adjuvant treatment: Does it work?

Diana Crivellari

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

Data from the National Institute of Canada IVIA.1 7 trial showed that patients who were disease free after 5 years of adjuvant treatment with tamoxifen had a 42% reduction of breast cancer recurrences (p <0.001) when they received a further treatment with the nonsteroidalJ aromatase inhibitor letrozole, immediately or within 3 montihs from the end of tamoxifen.

Original language	English
Pages (from-to)	237-240
Number of pages	4
Journal	Aging Health
Volume	4
Issue number	3
DOIs	https://doi.org/10.2217/1745509X.4.3.237
Publication status	Published - Jun 2008

Keywords

Aromatase inhibitors
Extended adjuvant therapy
Letrozole

ASJC Scopus subject areas

Medicine(all)
Geriatrics and Gerontology

Access to Document

10.2217/1745509X.4.3.237

Cite this

@article{062e2aa4a6a241d99f7fa4b9781569c1,

title = "Late-extended adjuvant treatment: Does it work?",

abstract = "Data from the National Institute of Canada IVIA.1 7 trial showed that patients who were disease free after 5 years of adjuvant treatment with tamoxifen had a 42% reduction of breast cancer recurrences (p <0.001) when they received a further treatment with the nonsteroidalJ aromatase inhibitor letrozole, immediately or within 3 montihs from the end of tamoxifen.",

keywords = "Aromatase inhibitors, Extended adjuvant therapy, Letrozole",

author = "Diana Crivellari",

year = "2008",

month = jun,

doi = "10.2217/1745509X.4.3.237",

language = "English",

volume = "4",

pages = "237--240",

journal = "Aging Health",

issn = "1745-509X",

publisher = "Future Medicine Ltd.",

number = "3",

}

TY - JOUR

T1 - Late-extended adjuvant treatment

T2 - Does it work?

AU - Crivellari, Diana

PY - 2008/6

Y1 - 2008/6

N2 - Data from the National Institute of Canada IVIA.1 7 trial showed that patients who were disease free after 5 years of adjuvant treatment with tamoxifen had a 42% reduction of breast cancer recurrences (p <0.001) when they received a further treatment with the nonsteroidalJ aromatase inhibitor letrozole, immediately or within 3 montihs from the end of tamoxifen.

AB - Data from the National Institute of Canada IVIA.1 7 trial showed that patients who were disease free after 5 years of adjuvant treatment with tamoxifen had a 42% reduction of breast cancer recurrences (p <0.001) when they received a further treatment with the nonsteroidalJ aromatase inhibitor letrozole, immediately or within 3 montihs from the end of tamoxifen.

KW - Aromatase inhibitors

KW - Extended adjuvant therapy

KW - Letrozole

UR - http://www.scopus.com/inward/record.url?scp=48249104017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249104017&partnerID=8YFLogxK

U2 - 10.2217/1745509X.4.3.237

DO - 10.2217/1745509X.4.3.237

M3 - Article

AN - SCOPUS:48249104017

SN - 1745-509X

VL - 4

SP - 237

EP - 240

JO - Aging Health

JF - Aging Health

IS - 3

ER -

Late-extended adjuvant treatment: Does it work?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this